ADHD drug trial for preschoolers pulled before it started
NCT ID NCT07169162
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test whether ADZENYS XR-ODT, a once-daily amphetamine tablet that dissolves in the mouth, could help manage ADHD symptoms in children aged 4 to less than 6 years. The trial was planned as a randomized, double-blind, placebo-controlled study, but it was withdrawn before enrolling any participants. As a result, no data or conclusions are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ADZENYS XR-ODT (amphetamine, an extended-release tablet that dissolves in the mouth)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT HYPERACTIVITY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada, 89128, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gentle massage at bedtime help kids with ADHD sleep?
- Do weighted blankets unlock better sleep for kids with ADHD?
- Smartphone app may boost parenting skills for child outbursts
- Can a Once-Daily pill tame ADHD and emotional storms?
- Could a phone app help parents of kids with special needs thrive?
- Could a Self-Help guide transform parenting stress for families of kids with NDD?